COMP <GO>
XRAY vs ABBV // EV/EBITDA & P/E VALUATION
DENTSPLY SIRONA Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: XRAY 2
— ABBV 9
■ METRIC PARITY
LAST: $9.61 (+1.80%) • MKT CAP: $1.92B
valuation
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XRAY VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XRAY | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.00% | 70.20% | -20.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.00% | 29.00% | -40.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 12.27% | 3.47% | +8.80 | XRAY | /fcf-yield <GO> |
| Operating Margin | -11.50% | 24.60% | -36.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -16.20% | 6.90% | -23.10 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -3.00% | 8.60% | -11.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 6.68% | 2.27% | +4.41 | XRAY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.33 | -4.88 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.1 | 65.1 | -10.03 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.92B | $513.86B | -$511.94B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XRAY REV | ABBV REV | XRAY GROSS % | ABBV GROSS % | XRAY FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.68B | $61.16B | 50.0% | 70.2% | $235.0M | $17.82B |
| FY 2024 | $3.79B | $56.33B | 51.6% | 70.0% | $461.0M | $17.83B |
| FY 2023 | $3.96B | $54.32B | — | — | $377.0M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XRAY // BETA —
ABBV // BETA 1.15